{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:54:10Z","timestamp":1777578850863,"version":"3.51.4"},"reference-count":23,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2010,10,9]],"date-time":"2010-10-09T00:00:00Z","timestamp":1286582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Ophthalmology"],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>TO determine the role of intravitreal bevacizumab injected at the time of cataract surgery on postoperative increase of retinal thickness in patients with diabetic retinopathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were randomized to a standardized procedure of phacoemulsification with intraocular lens implantation alone (control group; 30 eyes) or to receive 1.25 mg intravitreal bevacizumab at the end of surgery (IVB group; 31 eyes). Efficacy measures included best-corrected visual acuity (BCVA) testing, optical coherence tomography (OCT), and ophthalmoscopic examination at each postoperative visit during a 6-month follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were no significant differences in central macular thickness, BCVA, or systemic condition between the control and IVB groups at baseline. One month after surgery, the control group showed a significant increase in central macular thickness, whereas the bevacizumab group did not show an increase. After 6 months, there was no significant difference in macular thickness and postoperative visual acuity between the 2 groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Intravitreal administration of 1.25 mg bevacizumab at the time of cataract surgery is effective just for the short term and 6-month results are the same as the control group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5301\/ejo.2010.1405","type":"journal-article","created":{"date-parts":[[2010,10,31]],"date-time":"2010-10-31T09:10:19Z","timestamp":1288516219000},"page":"276-281","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":32,"title":["Prophylactic Intravitreal Bevacizumab for Diabetic Macular Edema (thickening) after Cataract Surgery: Prospective Randomized Study"],"prefix":"10.1177","volume":"21","author":[{"given":"Masoud Aghsaei","family":"Fard","sequence":"first","affiliation":[{"name":"Farabi Eye Research Center, Department of Ophthalmology, Tehran University of Medical Sciences, Tehran - Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza Yazdanei","family":"Abyane","sequence":"additional","affiliation":[{"name":"Farabi Eye Research Center, Department of Ophthalmology, Tehran University of Medical Sciences, Tehran - Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrdad","family":"Malihi","sequence":"additional","affiliation":[{"name":"Farabi Eye Research Center, Department of Ophthalmology, Tehran University of Medical Sciences, Tehran - Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,10,9]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1995.185"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-002-0520-9"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.10.1364"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.86.5.565"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.08.053"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)90148-3"},{"key":"e_1_2_1_8_2","first-page":"435","article-title":"Retinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitus","volume":"97","author":"Borrillo J.L.","year":"1999","unstructured":"BorrilloJ.L., MittraR.A., DevS. Retinopathy progression and visual outcomes after phacoemulsification in patients with diabetes mellitus. Trans Am Ophthalmol Soc 1999; 97: 435\u201345.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-002-0530-7"},{"key":"e_1_2_1_10_2","first-page":"829","article-title":"Progression of diabetic retinopathy after phacoemulsification in diabetic patients: a three-year analysis","volume":"26","author":"Liao S.B.","year":"2003","unstructured":"LiaoS.B., KuW.C. Progression of diabetic retinopathy after phacoemulsification in diabetic patients: a three-year analysis. Chang Gung Med J 2003; 26: 829\u201334.","journal-title":"Chang Gung Med J"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(03)00568-2"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(13)38012-9"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(13)38011-7"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-007-0688-0"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.03.003"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.117.12.1600"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2004.12.054"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.02.015"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00006982-200603000-00004"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.03.016"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2009.01.014"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e31819c6302"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318158ea28"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2008.09.019"}],"container-title":["European Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.5301\/EJO.2010.1405","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.5301\/EJO.2010.1405","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:35:48Z","timestamp":1777404948000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.5301\/EJO.2010.1405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,9]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["10.5301\/EJO.2010.1405"],"URL":"https:\/\/doi.org\/10.5301\/ejo.2010.1405","relation":{},"ISSN":["1120-6721","1724-6016"],"issn-type":[{"value":"1120-6721","type":"print"},{"value":"1724-6016","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,9]]}}}